Compounds, Compositions, Methods, and Uses for Treating Cancer and Immunological Disorders
Summary
The European Patent Office granted Patent EP3820533A2 to IL-2RX, Inc. covering novel compounds and compositions for treating cancer and immunological disorders. The patent application, filed by inventors Soares and Hurt, was published April 8, 2026 under IPC classifications A61K 47/64, A61K 47/65, A61P 35/00, and A61P 37/02. The patent is designated for all EU member states and extended territories.
What changed
EPO published patent application EP3820533A2 for IL-2RX, Inc., covering therapeutic compounds and compositions for cancer treatment and immunological disorders. The A2 publication indicates the application is open for third-party observations during the opposition period.
Pharmaceutical companies and biotech firms developing interleukin-based cancer therapies or immunological disorder treatments should monitor this patent for potential freedom-to-operate implications in EU markets. The patent's broad claims under A61K 47/64 and A61K 47/65 (protein-polymer conjugates and protein complexes) may affect similar therapeutic development programs.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS
Publication EP3820533A2 Kind: A2 Apr 08, 2026
Applicants
IL-2RX, Inc.
Inventors
SOARES, Luis R.B., HURT, Clarence Ray
IPC Classifications
A61K 47/64 20170101AFI20210225BHEP A61K 47/65 20170101ALI20210225BHEP A61P 35/00 20060101ALI20210225BHEP A61P 37/02 20060101ALI20210225BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.